Acadia Pharmaceuticals | ACAD - Assets


Acadia Pharmaceuticals reported $1.33B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Eisai JPY 1.44T 28.38B Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Incyte USD 6.33B 509M Sep/2025
J&J USD 192.82B 573M Sep/2025
Moderna USD 12.14B 125M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Prothena USD 352.63M 46.44M Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025